5% Lidocaine Medicated Plaster Use in Children with Neuropathic Pain from Burn Sequelae. Issue 3 (28th December 2012)

• Record Type: Journal Article
• Authors: Orellana Silva, Matias; Yañez, Veronica; Hidalgo, Gabriela; Valenzuela, Fernando; Saavedra, Rolando
• Is Part Of: Pain medicine. Volume 14:Issue 3(2013)
• Page Start: 422
• Page End: 429
• Publication Date: 2012-12-28
• Subjects: Pain -- Periodicals; Pain -- Treatment -- Periodicals; Analgesics -- Periodicals; Pain -- Periodicals; Pain Management -- Periodicals; Douleur -- Périodiques; Douleur -- Traitement -- Périodiques; Analgésiques -- Périodiques; Analgésique; Soulagement de la douleur; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.047205
• DOI: 10.1111/pme.12020
• Languages: English
• ISSNs: 1526-2375

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="pme12020-sec-0001" sec-type="section"> <title>Objective</title> <p>Neuropathic pain is a challenge in children with burn sequelae. Although relatively infrequent, the intensity and chronicity of neuropathic pain negatively impact functionality and quality of life. The use of 5% lidocaine medicated plaster has not previously been reported in children. We explored the effectiveness and safety of 5% lidocaine medicated plaster to treat neuropathic pain in children with burn sequelae.</p> </sec> <sec id="pme12020-sec-0002" sec-type="section"> <title>Design</title> <p>Three‐month prospective, uncontrolled study.</p> </sec> <sec id="pme12020-sec-0003" sec-type="section"> <title>Setting</title> <p>Corporation of Aid to Burned Children (COANIQUEM), a nonprofit pediatric burn rehabilitation center in Chile.</p> </sec> <sec id="pme12020-sec-0004" sec-type="section"> <title>Subjects</title> <p>Fourteen pediatric patients with burn sequelae neuropathic pain.</p> </sec> <sec id="pme12020-sec-0005" sec-type="section"> <title>Outcome Measures</title> <p>Demographics, burn and pain evolution (type, intensity [using Wong‐Baker FACES], and Douleur Neuropathique 4 [DN4]), and patient functionality. Plasma lidocaine levels were measured at 0, 12, 36, and 60 hours after treatment commencement.</p> </sec> <sec id="pme12020-sec-0006" sec-type="section"> <title>Results</title> <p>Fourteen patients were evaluable for plasma lidocaine levels. Twelve patients were available for clinical assessment (two patients lost to follow‐up) [mean (standard deviation)]: age, 11 years 7 months (2 years 6 months); weight, 45 kg (11.9 kg); burn evolution, 5 years 6 months (4 years); time between burn and pain onset, 3 years 6 months (3 years 2 months); time between pain onset and treatment, 5.1 months (4.8 months); lidocaine, between < and ½ plaster; initial pain intensity (FACES), 6.8 (1.6); final pain intensity, 0 in 11/12 patients; DN4, initial‐6, final‐2.3. All patients reported improved functionality. Plasma lidocaine levels were ≤27.45 ng/mL (>180 times below critical levels). No adverse reactions occurred.</p> </sec> <sec id="pme12020-sec-0007" sec-type="section"> <title>Conclusions</title> <p>These are the first published data suggesting that 5% lidocaine medicated plaster improves patient functionality, and is effective and safe for the treatment of neuropathic pain in pediatric patients with burn sequelae.</p> </sec> </abstract>